Dynamic clonal evolution of multiple bypass resistance mechanisms in EGFR-mutant lung adenocarcinoma: a case report - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evolving Clonal Resistance Mechanisms in EGFR-Mutant Lung Adenocarcinoma: Insights from a Case Study

  • By

  • Qingyun Zhang

  • Xiaoyan Yin

  • September 9, 2026

Share

  • 1

    A 62-year-old man with EGFR L858R-mutant lung adenocarcinoma developed resistance to aumolertinib, revealing complex clonal evolution.

  • 2

    Sequential resistance mechanisms included MET amplification, BRAF V600E mutation, and RET fusion, highlighting the heterogeneity of acquired resistance.

  • 3

    Dynamic next-generation sequencing (NGS) tracked the evolution of resistant clones, informing genotype-guided treatment modifications.

  • 4

    The patient experienced 11 months of progression-free survival with aumolertinib plus savolitinib before transient stabilization with selpercatinib.

  • 5

    The study emphasizes the importance of serial biopsy and NGS in managing acquired resistance to third-generation EGFR-TKIs.

Original Source(s)

Dynamic clonal evolution of multiple bypass resistance mechanisms in EGFR-mutant lung adenocarcinoma: a case report

  • by Qingyun Zhang, Xiaoyan Yin

  • September 9, 2026

Related Content

Molecular Diagnostics Go Mobile

A smartphone-linked fluorimeter detects infectious disease and cancer biomarkers in 10-minute assays

  • August 31, 2026

  • 3 min
Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis

Impact of patient-specific three-dimensional reconstruction on surgical planning and perioperative outcomes in early-stage lung cancer: a randomised clinical trial